Recent Phase 3 clinical trials (KEYNOTE-061) concluded the case with PD-L1 combined positive score (CPS) >10 had clinically significant results by the first line PD-L1 targeted therapy in a patient with unresectable advanced gastric cancer or recurrent gastric cancer [10]. Here, CD274 is linked to gastric cancer.